| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = -$1 ) |
| | 2024 | 2021 | VISIONARY PHARMACEUTICALS, INC | 10871 CORTE PLAYA SOLANA | SAN DIEGO | CA | 92124-4127 | SAN DIEGO | USA | R43CA243926 | Development of inhibitors of the SGK1 kinase, a critical target in anaplastic thyroid cancer | 000 | 1 | NIH | 3/7/2024 | -$1 |
|
| Issue Date FY: 2022 ( Subtotal = -$158,934 ) |
| | 2022 | 2021 | VISIONARY PHARMACEUTICALS, INC. | 10871 CORTE PLAYA SOLANA | SAN DIEGO | CA | 92124-4127 | SAN DIEGO | USA | R43CA243926 | Development of inhibitors of the SGK1 kinase, a critical target in anaplastic thyroid cancer | 001 | 1 | NIH | 5/12/2022 | $0 |
| | 2022 | 2019 | VISIONARY PHARMACEUTICALS, INC. | 10871 CORTE PLAYA SOLANA | SAN DIEGO | CA | 92124-4127 | SAN DIEGO | USA | R43CA247011 | Development of dual inhibitors of the kinases SGK1 and AKT1 for blockade of a critical pathway in triple-negative breast cancer | 000 | 1 | NIH | 5/10/2022 | -$158,934 |
| | 2022 | 2019 | VISIONARY PHARMACEUTICALS, INC. | 10871 CORTE PLAYA SOLANA | SAN DIEGO | CA | 92124-4127 | SAN DIEGO | USA | R43CA243926 | Development of inhibitors of the SGK1 kinase, a critical target in anaplastic thyroid cancer | 000 | 1 | NIH | 5/12/2022 | $0 |
| | 2022 | 2017 | VISIONARY PHARMACEUTICALS, INC. | 10871 CORTE PLAYA SOLANA | SAN DIEGO | CA | 92124-4127 | SAN DIEGO | USA | R43DK111290 | Identification of RORg drug candidates for the treatment of NASH | 000 | 2 | NIH | 5/18/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $86,262 ) |
| | 2021 | 2021 | VISIONARY PHARMACEUTICALS, INC. | 10871 CORTE PLAYA SOLANA | SAN DIEGO | CA | 92124-4127 | SAN DIEGO | USA | R43CA243926 | Development of inhibitors of the SGK1 kinase, a critical target in anaplastic thyroid cancer | 001 | 1 | NIH | 8/24/2021 | $86,262 |
| | 2021 | 2019 | VISIONARY PHARMACEUTICALS, INC. | 10871 CORTE PLAYA SOLANA | SAN DIEGO | CA | 92124-4127 | SAN DIEGO | USA | R43CA243926 | Development of inhibitors of the SGK1 kinase, a critical target in anaplastic thyroid cancer | 000 | 1 | NIH | 8/19/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $0 ) |
| | 2020 | 2019 | VISIONARY PHARMACEUTICALS, INC. | 8019 MONTARA AVE | SAN DIEGO | CA | 92126-1116 | SAN DIEGO | USA | R43CA243926 | Development of inhibitors of the SGK1 kinase, a critical target in anaplastic thyroid cancer | 000 | 1 | NIH | 9/21/2020 | $0 |
| | 2020 | 2017 | VISIONARY PHARMACEUTICALS, INC. | 8019 MONTARA AVE | SAN DIEGO | CA | 92126-1116 | SAN DIEGO | USA | R43DK111290 | Identification of RORg drug candidates for the treatment of NASH | 000 | 2 | NIH | 11/6/2019 | $0 |
| | 2020 | 2017 | VISIONARY PHARMACEUTICALS, INC. | 8019 MONTARA AVE | SAN DIEGO | CA | 92126-1116 | SAN DIEGO | USA | R43DK111290 | Identification of RORg drug candidates for the treatment of NASH | 001 | 2 | NIH | 7/21/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $599,982 ) |
| | 2019 | 2019 | VISIONARY PHARMACEUTICALS, INC. | 8019 MONTARA AVE | SAN DIEGO | CA | 92126-1116 | SAN DIEGO | USA | R43CA247011 | Development of dual inhibitors of the kinases SGK1 and AKT1 for blockade of a critical pathway in triple-negative breast cancer | 000 | 1 | NIH | 9/12/2019 | $299,982 |
| | 2019 | 2019 | VISIONARY PHARMACEUTICALS, INC. | 8019 MONTARA AVE | SAN DIEGO | CA | 92126-1116 | SAN DIEGO | USA | R43CA243926 | Development of inhibitors of the SGK1 kinase, a critical target in anaplastic thyroid cancer | 000 | 1 | NIH | 8/1/2019 | $300,000 |
| | 2019 | 2017 | VISIONARY PHARMACEUTICALS, INC. | 8019 MONTARA AVE | SAN DIEGO | CA | 92126-1116 | SAN DIEGO | USA | R43DK111290 | Identification of RORg drug candidates for the treatment of NASH | 000 | 2 | NIH | 1/29/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $0 ) |
| | 2018 | 2015 | VISIONARY PHARMACEUTICALS, INC. | 8019 MONTARA AVE | SAN DIEGO | CA | 92126-1116 | SAN DIEGO | USA | R44DK098896 | The Development of RORgt Immunomodulators Targeting the TH17 Axis in IBD- Phase 2 | 000 | 3 | NIH | 1/9/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $156,503 ) |
| | 2017 | 2017 | VISIONARY PHARMACEUTICALS, INC. | 8019 MONTARA AVE | SAN DIEGO | CA | 92126-1116 | SAN DIEGO | USA | R43DK111290 | Identification of RORg drug candidates for the treatment of NASH | 000 | 2 | NIH | 6/15/2017 | $156,503 |
|
| Issue Date FY: 2016 ( Subtotal = $143,482 ) |
| | 2016 | 2016 | VISIONARY PHARMACEUTICALS INC | 11555 SORRENTO VALLEY ROAD | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R43DK111290 | Identification of RORg drug candidates for the treatment of NASH | 000 | 1 | NIH | 9/6/2016 | $143,482 |
|
| Issue Date FY: 2015 ( Subtotal = $667,910 ) |
| | 2015 | 2015 | VISIONARY PHARMACEUTICALS INC | 11555 SORRENTO VALLEY ROAD | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R44DK098896 | The Development of RORgt Immunomodulators Targeting the TH17 Axis in IBD- Phase 2 | 000 | 3 | NIH | 8/27/2015 | $667,910 |
|
| Issue Date FY: 2014 ( Subtotal = $824,726 ) |
| | 2014 | 2014 | VISIONARY PHARMACEUTICALS INC | 11555 SORRENTO VALLEY ROAD | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R44DK098896 | The Development of RORgt Immunomodulators Targeting the TH17 Axis in IBD- Phase 2 | 000 | 2 | NIH | 9/10/2014 | $824,726 |
|
| Issue Date FY: 2013 ( Subtotal = $232,616 ) |
| | 2013 | 2013 | VISIONARY PHARMACEUTICALS INC | 11555 SORRENTO VALLEY ROAD | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R43DK098896 | DEVELOPMENT OF RORGT IMMUNOMODULATORS TARGETING THE TH17 AXIS IN IBD | 000 | 1 | NIH | 2/26/2013 | $232,616 |
|
|
